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Abstract
Pancreatic cancer (PC) is one of the deadliest cancers among both men and women.
However, if it is detected early, there is a significant increase in the 5-year survivability of the
disease1. Currently, there are no truly efficient detection mechanisms available to detect earlystage PC when treatment options are more viable. The first objective of this project was to
determine the expression levels of AHNAK2, IGHG3, EPPK1, CTHRC1, CEL, PLA2G1B, and
GNMT—all known to be aberrantly expressed in PC cell lines—in early-stage PC tissue and
assess the feasibility of their use as potential biomarkers for PC. To accomplish this, total RNA
was extracted from the tumor samples and their expression was analyzed using RT-qPCR. The
second objective was to determine the effects that the compound 1,2,3,4,6-Penta-O-galloyl-β-Dglucopyranoside (PGG) has on PC cell lines by counting the number of viable cells remaining
after exposure to varying concentrations of PGG. It was found that the genes IGHG3 and
CTHRC1, if taken together, may be able to identify the majority of early-stage PCs.
Additionally, it was discovered that PGG has a significant effect on PC cell survivability. The
EC50 value for BxPC-3 cells treated with PGG was determined to be 0.012 mg/mL and PGG was
shown to significantly increase the expression levels of GNMT. Additional analysis of the
expression levels of IGHG3 and CTHRC1 in blood samples will help provide further
information about their viability as potential biomarkers for PC.
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Introduction
Pancreatic Cancer (PC) is an extremely deadly disease with no truly efficient detection
mechanisms. As of 2013, PC was the fourth deadliest cancer for both men and women, claiming
the lives of more than 51,000 people across the United States alone 2. This high mortality rate is
principally due to difficulties in detecting PC during its earliest stages of development. This
difficulty in detection largely stems from how PC produces very few symptoms early on making
it extraordinarily challenging to diagnose3. If PC is detected early, however, there is a significant
increase in survivability of the disease.
Between 2008 and 2013, the 5-year relative survival rate for PC diagnosed as localized,
regional, and distant was 34%, 12%, and 3%, respectively 1. Therefore, if PC is discovered earlier
prior to metastasis, patients are nearly three times as likely to survive five years than when
compared to a later diagnosis with tumor invasion of distant tissues already underway.
Developing reliable and effective testing is critical to increasing the early detection of PC when
treatment options are still possible and mortality rates are significantly lower.
Currently, there are limited options for the early detection of PC. One technique, a blood
test called “CancerSEEK,” has produced promising results for the detection of PC as early as
stage 1 using a panel of biomarkers4. However, detection of early-stage PC is still difficult, and
blood tests such as these are not commonly used for its detection. By identifying additional genes
whose expression levels are significantly altered in early-stage PC, the ability to detect PC could
be improved and survival rates could be increased.
Previously, research has been conducted in our laboratory on identifying novel genes that
are either considerably upregulated or downregulated in PC to isolate potential biomarkers and
targets for treatments. The genes AHNAK2, CTHRC1, IGHG3, and EPPK1 have been
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determined to be upregulated in PC cell lines5. Additionally, GNMT, CEL, and PLA2G1B have
been identified as being significantly downregulated in PC cell lines 6. However, little to no
research has been conducted into the expression levels of these genes in early-stage PC tissue
samples; therefore, quantifying the expression of these genes in early-stage PC tissue could
provide new insights into potential biomarkers as well as further information regarding gene
regulation in early-stage PC.
While identifying genes that are aberrantly regulated in PC could help to increase the
disease’s early detection rate, discovering methods to renormalize or alter the expression of these
genes is also important. If a gene is found to be critical to the progression of PC, having the
ability to alter its expression could lead to potential therapeutic interventions. Previously, work
in our laboratory has shown that the gene GNMT (Glycine N-methyltransferase) is highly
downregulated in PC cell lines6. Furthermore, its expression in hepatocellular carcinoma has
been shown to be upregulated in the presence of 1,2,3,4,6-Penta-O-galloyl-β-D-glucopyranoside
(PGG), which is a potent inhibitor of these cells7. Understanding the effects of PGG on GNMT
and PC cell survival could help to provide additional information pertaining to its possible role in
the therapeutic treatment of PC.
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Purpose
While PC is one of the lesser diagnosed cancers among American individuals, it has one
of the highest mortality rates of all cancers. Early detection of PC, while difficult, could help
decrease its mortality rate and save countless lives. Previously, the genes EPPK1, CTHRC1,
IGHG3, and AHNAK2 have been shown to be highly upregulated in human PC cell lines 5 while
the genes GNMT, PLA2G1B, and CEL have been shown to be highly downregulated in PC cell
lines6. Along with this, the potent inhibitory effects of the compound PGG against hepatocellular
carcinoma has been linked to increases in GNMT expression levels 7. This project aims to
determine the expression levels of the aforementioned genes in early-stage PC tissue samples
and identify the impact of PGG on cell viability and GNMT expression in the PC cell line BxPC3. Identification of genes significantly upregulated or downregulated, specifically in early-stage
PC, could provide new therapeutic targets for treatment as well as potential biomarkers to help
increase the early detection of PC and disease survivability.

Research Questions to be Answered


What is the impact of PGG on BxPC-3 cell survivability?



How does BxPC-3 cell exposure to PGG impact GNMT expression?



Are the genes AHNAK2, IGHG3, CTHRC1, and EPPK1 significantly upregulated in
early-stage PC tissue samples?



Are the genes GNMT, PLA2G1B, and CEL significantly downregulated in early-stage
PC tissue samples?
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Literature Review
Altered gene regulation—where genes become either upregulated or downregulated in
cells—is a predominate pathway leading to the development of cancer. However, if genes that
are critical to the continued growth of cancer cells are identified and their regulation
renormalized, it is possible that the afflicted cell could take corrective action and undergo
apoptosis. Identifying these genes and mechanisms to renormalize their regulation, especially in
the early stages of cancer growth, is an important step in the continued quest to decrease the
mortality rates associated with all cancers, including PC. While multiple genes have been
identified to either be upregulated or downregulated in PC, many of their expression levels in
early-stage tissue samples have yet to be quantified.

Genes Associated with Being Upregulated in PC
AHNAK nucleoprotein 2 (AHNAK2) is a protein-coding gene that is responsible for the
production of a nucleoprotein thought to be important in the calcium signaling process by
associating itself with calcium channel proteins8. AHNAK2 was first shown to be upregulated in
PC through a bioinformatic analysis of microarray datasets conducted in our laboratory 5. This
result was later confirmed when the gene was shown to be significantly upregulated in PC cell
lines9. Later, multiple studies analyzed the expression of AHNAK2 in tissue samples from
patients with PC and have shown that AHNAK2 may be a potential prognostic biomarker for
patients with PC Ductal Adenocarcinoma7,10. Additional research into the expression levels of
AHNAK2 in early-stage PC will help to provide more information about its feasibility and utility
as a potential PC biomarker.
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Epiplakin 1 (EPPK1) is a protein-coding gene located on chromosome 8 within the
human genome. This gene is responsible for encoding a protein which is involved in the
organization of the cytoskeletal architecture of human cells 11. Furthermore, the protein encoded
by EPPK1 “may function to maintain the integrity of keratin intermediate filament networks in
epithelial cells”11. In a study conducted using microarray pancreatic cancer datasets, EPPKI was
shown to be one of the genes most significantly upregulated when compared to normal
pancreatic tissue5. After this discovery, EPPK1 was shown to be upregulated in pancreatic cancer
cell lines using RT-qPCR9. However, research into the expression levels of EPPK1, specifically
in early-stage PC tumors, is absent.
Collagen triple helix repeat containing 1 (CTHRC1) is another protein-coding gene
associated with being upregulated in PC. The protein that CTHRC1 encodes for works in
vascular remodeling, specifically when arterial damage has occurred 12. In 2014, CTHRC1 was
shown to be upregulated in PC microarray datasets5. Additionally, it has been shown to be
aberrantly expressed in a variety of other types of cancerous tumors and even has been shown to
promote PC progression13. Work to determine the expression of CTHRC1 in early-stage PC
could be expanded upon to help further define its activity levels and its suitability as a potential
biomarker for PC.
Immunoglobulin heavy constant gamma 3 (IGHG3) is a gene on chromosome 14
associated with PC. IGHG3 is a variant of Immunoglobulin 3 and is primarily associated with the
immune system. The protein encoded by IGHG3 helps in recognizing foreign antibodies,
initiates immune responses, and is found in the heavy chain of an immunoglobulin molecule 14.
Before being discovered as associated with PC, IGHG3 was shown to be associated with
mesothelioma15. More recently, it has been shown to be significantly upregulated in PC
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microarray datasets5. It is currently unknown why this gene, which is more commonly associated
with the immune system, is specifically upregulated in PC cells. Again, however, data indicating
the expression of IGHG3 in early-stage PC tissue is lacking.

Genes Associated with Being Downregulated in PC
Glycine N-methyltransferase (GNMT) is a protein-coding gene located on chromosome 6
of the human genome, and the protein that GNMT codes for is found in an enzyme located
within the cytoplasm of cells as a homotetramer16. Furthermore, the protein helps to catalyze the
conversion of S-adenosyl-L-methionine and glycine to S-adenosyl-L-homocysteine and
sarcosine16. In 2015, GNMT was found to be abnormally methylated in PC tissue samples
causing the enzyme it encodes for to be downregulated in 87% of cases 17. More recently, GNMT
was found to be downregulated in PC cell lines through the use of RT-qPCR 6. Interestingly,
GNMT expression has been determined to be affected by the compound PGG 7. While PGG has
been studied in a variety of different tissue types, mostly examining its potential for cancer
treatment, it has not been significantly investigated in PC. If GNMT is found to be significantly
downregulated in PC tissue, PGG could be a potential mechanism to therapeutically alter the
expression levels of this tumor suppressor gene back to a more normal range.
Carboxyl ester lipase (CEL) is another protein-coding gene that is highly downregulated
in PC. CEL codes for a protein that is secreted from the pancreas which helps in the absorption
and hydrolysis of cholesterol and lipid-soluble vitamins within the digestive tract 18.
Phospholipase A2 group 1B (PLA2G1B) is a protein-coding gene that is also responsible for
coding for an enzyme, secreted by the pancreas, that helps to catalyze the hydrolysis of
membrane glycerophospholipids to release arachidonic acid and lysophospholipids 19.
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In 2017, copy number variants of CEL were identified as risk factors for PC 20. Later in
2018, CEL, along with PLA2G1B, was identified as being significantly downregulated in PC cell
lines6. Most recently, CEL and PLA2G1B were both identified as being downregulated in tissue
samples21. Further research into CEL and PLA2G1B and their expression levels in early-stage
PC will help to provide additional insights into their potential feasibility as early-stage PC
biomarkers and utility as targets for therapeutic intervention.
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Methodology
Quantification of Gene Expression in Early-Stage PC Tumor Tissue
Isolation of Total RNA from Early-Stage Tumor Tissue
Seven paired early-stage PC tumor samples (mass ranges around 30 mg) were obtained
from the University of Iowa Hospitals and Clinics. Total RNA isolation was conducted on these
samples following a procedure using the Qiagen RNeasy Micro Kit and structured around the
Qiagen RNeasy Handbook with some modifications22. These modifications were due to the
methods development process conducted in our laboratory because of the significant presence of
RNases in the pancreas and tumor samples.
First, in a cold room at 4°C, 900 μL of a solution containing 1 mL Buffer RLT to 50 μL
of ß-Mercaptoethanol (RLT:ME) was pipetted into the 2-mL centrifuge tubes containing the
tissue samples. Tissue homogenization was then conducted using a tissue homogenizer (Qiagen
TissueRuptor II) set on low for 10 seconds and whose probes had been previously sterilized with
a 70% ethanol solution and allowed to dry. This mixture was transferred to a plastic, roundbottomed test tube with an approximate size of 1.25 cm by 14 cm. The centrifuge tube was
washed with another 900 μL of RLT:ME solution, and the solution was then transferred to the
plastic test tube. Following this, tissue disruption was carried out using the tissue homogenizer
set at full speed for 1 minute on the RLT:ME tissue sample mixture. In order to achieve complete
disruption, the probe was moved in a circular, up and down type pattern during all tissue
disruption events.
The sample was placed on ice and, outside the cold room, transferred to a 2 mL
microcentrifuge tube and centrifuged at 13,200 rpm for 3 minutes. Next, the supernatant was
transferred, in aliquots of 900 μL, to two new 2 mL microcentrifuge tubes. 900 μL of 70%
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ethanol was added to each sample and mixed by pipetting. Next, 700 μL of the sample was then
added to a RNeasy Spin Column and centrifuged for 15 seconds at 10,000 rpm. The flowthrough was discarded and another 700 μL of the sample was placed into the spin column and
centrifuged using the same settings as before. Finally, the flow-through was discarded, the
remaining volume of sample was run through the spin column using the previous settings, and
the flow-through of this final run was discarded.
After running the entire volume of sample through the spin column, 700 μL of Buffer
RW1 was added to it, centrifuged for 15 seconds at 10,000 rpm, and the flow-through was
discarded. Next, 500 μL of Buffer RPE was added to the spin column and the tube was
centrifuged for 15 seconds at 10,000 rpm. The flow-through was discarded. Following this, an
additional 500 μL of Buffer RPE was added to the spin column, centrifuged for 2 minutes at
10,000 rpm, and the flow-through was discarded. The spin column was again centrifuged for 1
minute at 13,200 rpm to ensure complete drying of the column and was then immediately placed
into a 1.5 mL microcentrifuge collection tube. 30 μL of RNase-free water was added to the spin
column membrane and centrifuged for 1 minute at 10,000 rpm. Immediately following RNA
isolation, total RNA yields were quantified by UV Spectroscopy using a Nanodrop
spectrophotometer (Thermo Fisher) calibrated with 2 μL of RNase free water.

Conversion of Isolated RNA to cDNA
Isolated RNA for each sample was converted to cDNA using a reverse transcription
process. To accomplish this, the iScript cDNA Synthesis Kit (Bio-Rad) was used and the
procedure was carried out following the suggested manufacturer protocol 23. The only alteration
to this procedure was in the amount of RNA used. Due to early difficulties in Real Time-
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quantitative Polymerase Chain Reaction (RT-qPCR) reproducibility caused by high Ct values,
the amount of RNA was increased to 2 μg for samples which had a sufficient amount of
extracted RNA available for use. Samples with smaller amounts of extracted RNA were reduced
as needed to accommodate the lower yields from these samples with an emphasis on using the
most RNA possible to lower the Ct value for all samples and increase their reproducibility.

Analysis of gene expression using RT-qPCR
Gene expression in each paired PC tissue sample (tumor and normal) was quantified
using RT-qPCR. RT-qPCR was carried out using iTaq Universal Sybrgreen Supermix and done
following the manufacturer’s suggested procedure 24. Each reaction was conducted in
quadruplicate with a total reaction volume of 20 μL. Furthermore, each gene tested was prepared
with a master mix containing iQ SYBR Green Supermix, sterile nuclease-free water, template
DNA, and forward and reverse primers as illustrated in Table 1. If multiple genes were to be
analyzed, the volumes shown in Table 1 were multiplied by the number of genes being tested to
calculate the total reagent volumes for each sample needed.

Reagent

Master Mix For Each Gene (μL)

iQ SYBR Green Supermix

46.8

Template DNA

3.8

Sterile Nuclease-Free Water

41.2

Primers (Forward and Reverse)

1.7

Total Volume

93.5

Table 1: Reagent volumes for RT-qPCR
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Master mixes for each sample were split up by gene and then had the appropriate primer
added to them. This process is shown in more detail below in Figure 1. It should be noted that
primer volumes are always 1.7 μL and are added after the separation of the original master mix
as indicated in the manufacturer’s protocol24.

Master Mix (Normal Tissue)

Master Mix (Tumor Tissue)








SYBR Green
Sterile Water
Template DNA (Tumor Tissue)

Master Mix
(Tumor Tissue Gene X)

Master Mix
(Tumor Tissue Gene Y)







Tumor Tissue Master Mix
Primer (Gene X)

Tumor Tissue Master Mix
Primer (Gene Y)

SYBR Green
Sterile Water
Template DNA (Normal Tissue)

Master Mix
(Normal Tissue Gene X)



Normal Tissue Master Mix
Primer (Gene X)

Master Mix
(Normal Tissue Gene Y)



Normal Tissue Master Mix
Primer (Gene Y)

Figure 1: Master mix allocation procedure for RT-qPCR

The master mixes were then aliquoted into four RT-qPCR wells on a 96 well plate. It was
found that flicking each master mix 10 times before each centrifuge step and mixing by pipetting
before all master mixes were aliquoted produced the most consistent and reproducible results.
After aliquoting all samples into the 96 well plate, the plate was sealed with a coverslip which
was pressed firmly and evenly over the entire surface to remove all bubbles. Any bubbles in the
solutions in the wells were removed by flicking and the entire plate was then centrifuged for 40
seconds at 3300 rpm. The set-up for the RT-qPCR process was as follows: initially, the
temperature was set at 50.0°C for 2 minutes and then increased to 95.0°C for 10 minutes for
initial denaturing and enzyme activation. Following this, 40 cycles of denaturing at 95.0°C for 15
seconds accompanied by an annealing and extension stage at 60.0°C for 45 seconds was
performed. This procedure was the same for each sample and gene tested. The gene GAPDH was
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used to normalize each paired sample. RT-qPCR primers for all genes tested are shown in Table
2 below. Finally, these results were then analyzed for significance using the student’s t-test.
Gene

Forward Primer

Reverse Primer

CTHRC1

5’-CAATGGCATTCCGGGTACAC-3’

5’-GTACACTCCGCAATTTTCCCAA-3’

IGHG3

5’-AGGACTCTACTCCCTCAGCA-3’

5’-GGCATGTGTGAGTTGTGTCA-3’

EPPK1

5’-GTACGAGCGGTTGGAGCAT-3’

5’-TGTTTGCTTTTGGGTCGATGA-3’

GAPDH

5’-CCATGTTCGTCATGGGTGTG-3’

5’-CAGGGGTGCTAAGCAGTTGG-3’

AHNAK2

5’-GATGTGCGACTGCTTCCAC-3’

5’-CAGCCTCAGTCGTGTATTCG-3’

GNMT

5’-ACTGGATGACTCTGGACAA-3’

5’-ACTGAGGATGTGGTCGT-3’

CEL

5’-GTCACCTTCAACTACCGTGTC-3’

5’-GGCCGCGATATTCCTCTTCAC-3’

PLA2GB1

5’-AAATGATCAAGTGCGTGATCC-3’

5’-TTGCTGCTACAGGTGATTGC-3’

Table 2: Forward and reverse primers for RT-qPCR

PGG Impact on PC Cell Line BxPC-3
Cell Maintenance
The PC cell line BxPC-2, previously acquired from the American Type Culture
Collection, was reconstituted from frozen stocks and grown in RPMI Medium 1640. The cell
media was additionally supplemented with 1% Penicillin-Streptomycin solution along with 10%
Fetal Bovine Serum. The cells were kept at 37°C in an atmosphere of 5% CO 2 and were split as
needed to ensure that cell confluency never exceeded 80%.

Determination of the EC50 Value
When determining the impact that PGG has on BxPC-3 cell survival, initially 300,000
cells were added to each well in a 6-well tissue culture plate conducted in triplicate. For example,
three 6-well tissue culture plates were used each containing 300,000 cells/well along with 1.5mL
of cell media. After 24 hours of uninterrupted growth, PGG was added in concentrations of
0.1mg/mL, 0.05mg/mL, 0.025mg/mL, 0.012mg/mL, and 0.006mg/mL along with a control well
12

containing no PGG, all in triplicate. The PPG solution was made by initially diluting the
compound in solid form to a concentration of 5x in a 1:1 ethanol to water solution which was
subsequently diluted to a final volume containing 10% ethanol. After vortexing, small aliquots of
100 μL were created from this original master solution and used. The addition of PGG was
carried out by removing all cell media, washing each well with 1.5mL of Phosphate-buffered
saline (PBS), and lastly adding 1.5mL of fresh cell media containing the appropriate
concentrations of PGG.
The cells grew uninterrupted for 72 hours. After the specified time period, the wells were
washed with 1.5mL of PBS and the remaining cells were counted using a Bio-Rad TC10
Automated Cell Counter following the manufacturer’s suggested procedure 25. In our laboratory,
we observed that in the range of 50,000 cells/mL – 1,000,000 cells/mL, the results from the
TC10 Automated Cell Counter were consistent with those from a manual hemocytometer.

Quantification of PGG Impact on GNMT Expression
A 6-well cell culture plate seeded with 300,000 cells of BxPC-3 and 1.5mL of cell culture
media was allowed to grow for 24 hours. Next, PGG was introduced into the wells using the
same concentrations and procedure as described above. After growing in the PGG/cell media
solution for 24 hours, the cells were harvested, and total RNA extraction was conducted on each
sample per the Qiagen RNeasy Handbook using the Qiagen RNeasy Mini kit 22. Isolated RNA
was converted to cDNA using 1μg of RNA and following the procedure outlined for the tissue
samples. Finally, the gene expression of GNMT for each concentration of PGG was analyzed
using RT-qPCR following the same procedure described previously.
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Results and Discussion
The clinicopathological characteristics of all seven tissue samples are shown in Table 3
below. Based on the stage and grade identified in Table 3, all patients were considered to have
early-stage PC. As shown in the table below, the PC tissue samples were comprised of a nearly
even mix of samples from both male and female patients. Furthermore, the patients span a large
age range from 51 to 85 years of age.

Table 3: Clinicopathological characteristics of all patients that were utilized in this study. Additionally, the
grade and total size of the pancreatic tumor is also shown.

Genes IGHG3, CTHRC1, EPPK1, and AHNAK2
The expression levels of IGHG3 in the early-stage PC tissue samples, as determined by
RT-qPCR, is shown below in Figure 2. IGHG3 was determined to be significantly upregulated
(p<0.001) in 6 of the 7 tissue samples. Furthermore, 3 of these samples were upregulated by
more than 15x with sample S4 30x overexpressed when compared to normal pancreatic tissue
from the sample patient. These results are consistent with previous research focused on the
expression of IGHG3 in PC cell lines5.
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Figure 2: Expression levels of IGHG3 in early-stage PC tissue samples. **
indicates a p value <0.001

CTHRC1 also had samples where its expression was drastically upregulated. As shown in
Figure 3, CTHRC1 was upregulated (p<0.001) in 5 of the 7 samples tested. Similar to IGHG3,
CTHRC1 was also approximately 30x overexpressed in one of the samples when compared to
the control. Most importantly, when taken together, IGHG3 and CTHRC1 were overexpressed in
6 of the 7 samples with expression levels nearly 10x greater than that of the control. These
results indicate that IGHG3 and CTHRC1 could potentially function as early-stage PC
biomarkers for most types of PC.

Figure 3: Expression levels of CTHRC1 in early-stage PC tissue samples.
**p<0.001
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When compared to the results from IGHG3 and CTHRC1, EPPK1’s expression was not
as consistent. Figure 4 indicates that EPPK1 was significantly upregulated (p<0.001) in 3 of the
7 samples tested. These samples were overexpressed between 1.5x and 2x which is significantly
less than the overexpression observed for genes CTHRC1 and IGHG3. Additionally, EPPK1 was
significantly downregulated in 4 of the 7 samples. While EPPK1 was overexpressed in a panel of
7 PC cell lines, it did not exhibit similar behavior in early-stage PC tissue as nearly half of the
samples exhibited overexpression while the other samples were underexpressed 9.

Figure 4: Expression levels of EPPK1 in early-stage PC tissue samples. **p<0.001

While AHNAK2 was highly upregulated in PC cell lines, its expression levels in this
experiment were too low to enable accurate detection by RT-qPCR. Looking forward,
AHNAK2’s expression level in early-stage PC tissue samples could be evaluated using
techniques more sensitive than RT-qPCR. This could more accurately assess its regulation,
potential for use as a biomarker, and feasibility as a target for therapeutic treatment.
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Genes CEL, PLA2G1B, and GNMT
As shown in Figure 5, CEL mRNA was significantly underexpressed in 4 of the 7
samples and significantly overexpressed in the other three samples. While CEL was
downregulated in four samples, it was surprisingly overexpressed in the other three samples.
Previously, it had been shown in cell lines that CEL was significantly and consistently
underexpressed6. This result indicates that there are some early-stage PC tissues where CEL is
overexpressed. These findings impact its potential role as an early-stage PC biomarker due to its
inconsistent expression levels.

Relative Quantification

CEL
3
2.5
2
1.5
Control

1

Tumor

0.5
0

S1

S2

S3

S4

S5

S6

S7

Pancreatic Cancer Tissue Panel
Figure 5: Expression levels of CEL in early-stage PC tissue samples.

Along with CEL, Figure 6 shows that PLA2G1B was significantly underexpressed in 4 of
the 7 samples tested and overexpressed in only one sample. This result, like that from CEL, is
not in complete agreement with previous results analyzing the expression levels of PLA2G1B in
PC cell-lines6. This indicates the PLA2G1B would need to be paired with other genes in order to
act as a comprehensive early-stage biomarker.
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Relative Quantification

PLA2G1B
3
2.5
2
1.5
Control

1

Tumor

0.5
0

S1

S2

S3

S4

S5

S6

S7

Pancreatic Cancer Tissue Panel
Figure 6: Expression levels of PLA2G1B in early-stage PC tissue samples.

Finally, as illustrated in Figure 7, GNMT was significantly underexpressed in four
samples and overexpressed in the other three. This result, like that from the other genes
PLA2G1B and CEL, highlights their ability to detect approximately half of the early-stage PC
samples tested. However, all these genes would need to be strategically paired with other genes
that are capable of detecting the remaining samples to develop a comprehensive biomarker test
that can accurately identify a large majority of early-stage PCs.
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Figure 7: Expression levels of GNMT in early-stage PC tissue samples.
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Interestingly, there seems to be a pattern in the expression of CEL, PLA2G1B, and
GNMT. PLA2G1B was underexpressed in the same four samples (S1, S2, S4, and S5) as CEL.
Furthermore, they were both overexpressed by nearly the same amount in sample S3. Finally, the
expression levels of GNMT seemed to be strikingly similar to the results of CEL. Specifically,
both CEL and GNMT were underexpressed in samples S1, S2, and S4 while both being
significantly overexpressed in samples S4 and S7. Finally, all three genes were overexpressed in
sample S4. This result suggests some sort of underlying similarity between samples S1 through
S5 with respect to the genes CEL, PLA2G1B, and GNMT. The mechanism causing the similar
expression of these genes in early-stage PC could be investigated in the future and may reveal
more information about a common way that early-stage PC impacts gene regulation in the
pancreas.
Overall, these results indicate that IGHG3 and CTHRC1, when taken together, may be
able to identify the majority of early-stage PCs. In addition to this, further testing needs to be
conducted, specifically concerning the expression of these genes in blood or plasma samples. If
these genes could be isolated and shown to be significantly upregulated in patient blood samples,
the prospect of a biomarker test utilizing both IGHG3 and CTHRC1 would be significantly
increased.
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GNMT and the Effect of PGG
As explained previously, the PC cell line BxPC-3 was treated with varying
concentrations of PGG and the impact that this had on the cell’s viability was determined. The
results from this are shown below in Figure 8 where the EC 50 value is 0.012 mg/mL.

Figure 8: Impact of PGG on the survivability of PC cells BxPC-3. The EC50 value is 0.012 mg/mL.

After identifying that PGG was indeed responsible for the death of PC cells, the impact
that PGG had on the expression levels of GNMT was analyzed using RT-qPCR. As shown in
Figure 9, a PGG concentration of 0.012 mg/mL nearly doubled the expression level of GNMT.
Furthermore, when the concentration of PGG was doubled again, the expression levels of GNMT
approximately doubled from the previous concentration. These relationships show that PGG is
having a significant impact on the expression levels of GNMT in PC cell line BxPC-3.
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Figure 9: Impact of PGG on the expression levels of GNMT mRNA in BxPC-3 cell line.

Based on these results, it seems that PGG has a significant ability to alter the gene
expression of GNMT in PC cells while also promote cell death. These results help to show that
PGG may have potential as a therapeutic treatment for PC. However, more testing needs to be
conducted on the impact of PGG on regular pancreatic cells, isolation of GNMT as a plasmid
vector to conclusively determine that PGG is directly affecting its expression levels, and further
gene analysis to see other effects that PGG is having on the PC cells.
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Conclusions
The purpose of this project was to identify genes aberrantly expressed in early-stage PC
and evaluate the effectiveness of PGG as a possible therapeutic for the treatment of PC. The
genes IGHG3 and CTHRC1, when taken together, may be able to identify a large majority of
early-stage PC. Due to the limitations of this project, blood and plasma samples were not able to
be tested for the expression levels of IGHG3 and CTHRC1. However, additional research
focused on assessing their expression levels here would provide further information about their
ability to act as early-stage PC biomarkers. The genes PLA2G1B, CEL, and GNMT exhibited a
remarkable similarity in expression levels in 5 of the 7 early-stage tumor tissues analyzed.
Increased research into the cause of this similarity in expression levels may help reveal more
information about the impact that PC has on gene expression in the pancreas. Additionally, PGG
was shown to have a significant impact on the survivability of PC cells with an EC 50 value of
0.012 mg/mL. PGG significantly increased the expression levels of the gene GNMT in the PC
cell line BxPC-3. This result may indicate a possible pathway that causes the cytotoxic effects
that PGG has on the PC cells and should be further explored in the future. Overall, this research
provides more information pertaining to gene regulation in early-stage PC, indicates a possible
mechanism that could be used to alter the expression of GNMT in PC cells, and could potentially
lead to new biomarker testing capable of identifying early-stage PC. This information may help
to provide new insights and diagnostic capabilities for the treatment of PC in the future which
would ultimately decrease the mortality rate associated with the disease.
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